Lung Cancer Europe shared a post by Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, on X, adding:

“Really useful real-world US data on chemo plus immunotherapy in 1st line NSCLC. Appreciate Giannis Mountzios’s insights – helps frame the bigger picture. Always important to ask not just if something works, but who it’s for, and what the impact is.”

Quoting Giannis Mountzios‘s post:

“Can we quantify the harm-benefit ratio of adding chemo to IO in 1L advanced NSCLC? Was a pleasure to be invited by JAMA Oncology to comment on the cohort study of 17 681 pts by Hayward et al from John Hopkins Medicine.”

Title: Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

Authors: James Heyward, Catherine R. Lesko, Joseph C. Murray, Hemalkumar B. Mehta, Jodi B. Segal

Journal: JAMA Oncology

Read Original Article.

Giannis Mountzios

Title: Immunotherapy With or Without Chemotherapy in Advanced NSCLC—A Delicate Balance of Harm and Benefit

Journal: JAMA Oncology

Author: Giannis Mountzios

Read Full Commentary.

Giannis Mountzios

More posts featuring NSCLC on OncoDaily.

Giannis Mountzios: Can we quantify the harm-benefit ratio of adding chemo to IO in 1L advanced NSCLC?

“Really useful real-world US data on chemo plus immunotherapy in 1st line NSCLC. Appreciate Giannis Mountzios’s insights – helps frame the bigger picture. Always important to ask not just if something works, but who it’s for, and what the impact is.”

“Can we quantify the harm-benefit ratio of adding chemo to IO in 1L advanced NSCLC? Was a pleasure to be invited by JAMA Oncology to comment on the cohort study of 17 681 pts by Hayward et al from John Hopkins Medicine.”

“Can we quantify the harm-benefit ratio of adding chemo to IO in 1L advanced NSCLC? Was a pleasure to be invited by JAMA Oncology to comment on the cohort study of 17 681 pts by Hayward et al from John Hopkins Medicine.”